Peptide library

BPC-157
human studies

Every study we found that gave BPC-157 to people, published or registered, with its design, size and status, checked on 18 November 2026.

Short answerCompound research · 5 min read · Updated 18 Nov 2026

As of 18 November 2026, we found six studies that gave BPC-157 to people, with 118 participants in total, and four entries on ClinicalTrials.gov, none with posted results. The only randomised, placebo-controlled data are in conference abstracts on two studies, from 2002 to 2005. No peer-reviewed randomised controlled trial of BPC-157 has been published.

Key takeaways

  • We found six studies that gave BPC-157 to people, 118 participants in total, and four ClinicalTrials.gov entries (18 Nov 2026).
  • The only randomised, placebo-controlled data come from conference abstracts on two studies (2002 to 2005); FDA staff found the colitis trial’s data inadequate.
  • A 2026 systematic review of the three full papers rated the certainty of the evidence “very low”.
  • None of the four registered studies has posted results; a phase 2 trial is recruiting.
  • According to FDA staff, no serious adverse events appear to have been reported in the five studies they reviewed, but safety monitoring was unclear and the safety profile cannot be characterised.

01BPC-157 human studies at a glance

Every study we found that gave BPC-157 to people, counted on 18 November 2026 from PubMed, ClinicalTrials.gov and FDA’s 2026 review.

QuestionAnswer (18 Nov 2026)
Studies that gave BPC-157 to people6, two of them known only from conference abstracts summarised in FDA’s 2026 review
People in them, in total118, including placebo groups (32 + 53 + 16 + 12 + 2 + 3)
Randomised and placebo-controlled2, both known only from conference abstracts (2002–2005); no full peer-reviewed paper
Registry entries on ClinicalTrials.gov4: 1 completed, 1 recruiting, 1 not yet recruiting, 1 of unknown status
Registry entries with posted results0
Evidence tierT2: small human studies, most without a control group. The main evidence base is animal (T3)
Certainty, per a 2026 systematic review“Very low”

02Published human studies

FDA staff found five clinical studies when they reviewed BPC-157 for the July 2026 advisory committee. A 2026 case report adds a sixth. A 2026 systematic review, searching to 1 June 2026, included three full papers.

StudyDesignPeople (n)What was measuredControl group
Veljaca et al., 2002 and 2003 (conference abstracts)Phase 1, randomised, placebo-controlled32 healthy volunteers, 24 given BPC-157Tolerability and blood levelsPlacebo
Ruenzi et al., 2005 (conference abstract)Phase 2, randomised, double-blind, placebo-controlled, multicentre53 with mild to moderate ulcerative colitis; 46 completedA disease-activity scorePlacebo
Lee and Padgett, 2021Retrospective chart review with a phone survey16 with knee pain, 4 of whom also received thymosin β4Self-rated pain reliefNone
Lee, Walker and Ayadi, 2024Single-arm pilot12 women with interstitial cystitisA global response questionnaireNone
Lee and Burgess, 2025Pilot safety study2 adultsBlood tests and vital signsNone
Froum et al., 2026Case report3 dental patients with nerve injury, given several agents at onceRecovery of sensationNone

What FDA staff said. The studies “were of short duration, had small sample sizes”, and the authors “provided limited information on safety data”. On the colitis trial, known only from a meeting abstract, they concluded that the data “are therefore inadequate to support the efficacy and safety” of BPC-157 in that setting. In the two abstract-only studies, BPC-157 was reported as not detected, or mostly below the assay’s limit, in blood samples.

What the 2026 systematic review said. Reviewing the three full papers (30 people), the authors judged all three to be of poor methodological quality and rated the overall certainty of the evidence “very low”. None had a control group, so none can separate an effect of BPC-157 from natural recovery or expectation.

03Registered human studies

ClinicalTrials.gov lists four studies of BPC-157 in people. None has posted results.

RecordDesignPeoplePrimary outcomeStatusResults posted
NCT02637284Phase 1, randomised, placebo-controlled, blinded42 healthy volunteers (estimated)Adverse eventsUnknown; last updated December 2015No
NCT07752381Single group, no control, not blinded40 physically active adults (actual)Blood markers of inflammation (hs-CRP, IL-6) and self-reported swellingCompleted November 2025No
NCT07437547Phase 2, randomised, placebo-controlled, quadruple-blind120 adults with an MRI-confirmed hamstring strain (estimated)Time to return to sport; change in injury volume on MRIRecruiting since February 2026No
NCT07803250Phase 1, randomised, blinded30 adults after rotator cuff repair surgery (estimated)Shoulder strengthNot yet recruiting; planned start January 2027No

NCT07752381 tested a commercial product containing BPC-157, made by the study’s sponsor. For NCT02637284, FDA staff found no posted results and no associated published study. NCT07803250’s record is internally inconsistent: its summary describes 20 patients and a saline placebo, while its arms list a control group with no study product and an estimated enrolment of 30. A registration is a plan, not a result.

04Safety in these studies

FDA staff found that no serious adverse events appear to have been reported in the five studies they reviewed. They caution that safety monitoring for most of them “is unclear”, and concluded that “there is insufficient clinical safety information to characterize the safety profile” of BPC-157. In the healthy-volunteer abstracts, headache and flatulence were the most frequent adverse events, with no obvious difference from placebo.

Outside these studies, FDA found three FAERS reports through 4 December 2025, all involving injectable products: redness and swelling at the injection site in a person also using thymosin; shortness of breath leading to an emergency-room visit; and skin and gum darkening that came back when the person used a product containing BPC-157 and TB-500 again. FDA staff judged that last case “likely due to the drug product”, but, because the product contained two peptides, could not assess whether BPC-157 played a role, and wrote that FDA “cannot make definitive conclusions regarding the safety of BPC-157 based on FAERS data alone”.

FDA’s compounding page adds that BPC-157 “may pose risk for immunogenicity for certain routes of administration” and that the agency “lacks sufficient information to know whether the drug would cause harm when administered to humans”. If you have had a reaction to any peptide product: how to report it.

05What these studies can’t tell you

  • Whether BPC-157 works for any condition in people. The only randomised data sit in two conference abstracts: one was a tolerability study, and FDA staff found the other, in colitis, inadequate to support efficacy or safety.
  • Its safety over months or years. FDA staff describe the studies as short and small, with unclear safety monitoring.
  • How BPC-157 behaves in the human body. FDA staff found no human pharmacokinetic data for most routes, and in the two studies that measured blood levels BPC-157 was not detected or mostly below the assay’s limit.
  • What the registered trials will find. None has reported.

For the animal research and regulatory history, see the BPC-157 research guide and is BPC-157 legal?

Counts and statuses checked on 18 Nov 2026. This page summarises research. It is not medical advice.

RefSources

  1. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: BPC-157-related bulk drug substances. Advisory committee briefing, 2026 (pp. 27, 40–43, 54–55). www.fda.gov/media/193343/download
  2. Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg, 2026;92(3). PMID 42885452. pubmed.ncbi.nlm.nih.gov/42885452/
  3. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med, 2021;27(4):8–13. PMID 34324435. pubmed.ncbi.nlm.nih.gov/34324435/
  4. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med, 2024;30(10):12–17. PMID 39325560. pubmed.ncbi.nlm.nih.gov/39325560/
  5. Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med, 2025;31(5):20–24. PMID 40131143. pubmed.ncbi.nlm.nih.gov/40131143/
  6. Froum S, Estrin N, Pico G, et al. Case report: regenerative peptides for inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Front Oral Health, 2026;7:1907109. PMID 42876687. pubmed.ncbi.nlm.nih.gov/42876687/
  7. ClinicalTrials.gov. Search results for “BPC-157”: NCT02637284, NCT07752381, NCT07437547, NCT07803250. Registry search and records, read 18 Nov 2026. clinicaltrials.gov/search?term=BPC-157
  8. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Web page, content current as of 22 Apr 2026; read 18 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

Has BPC-157 been tested in humans?

In a handful of small studies. We found six studies with 118 participants in total; the only randomised, placebo-controlled data are in conference abstracts on two studies, and no peer-reviewed randomised trial has been published.

Are there any BPC-157 clinical trials?

Four studies are registered on ClinicalTrials.gov: one completed, one recruiting, one not yet recruiting and one of unknown status. None had posted results on 18 November 2026.

What side effects were reported in BPC-157 human studies?

According to FDA staff, no serious adverse events appear to have been reported in the studies, but safety monitoring was unclear in most of them. FDA’s FAERS database held three reports through December 2025, one of which FDA staff judged likely caused by a product that contained both BPC-157 and TB-500.

Why do sources give different counts of BPC-157 human studies?

It depends on what counts. FDA staff included studies known only from conference abstracts and found five; a 2026 systematic review included three full papers; a 2026 case report adds a sixth.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page